Chalasani N, Wo J M, Hunter J G, Waring J P
Department of Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Dig Dis Sci. 1997 Mar;42(3):603-7. doi: 10.1023/a:1018863529777.
Over the past two decades, the incidence of adenocarcinoma of the esophagus and gastric cardia has increased at a rate exceeding that of any other cancer. Barrett's esophagus is the only known risk factor for these malignancies. Recently, emphasis has been placed on the significance of specialized intestinal metaplasia (SIM) on esophageal biopsies. Our aim was to compare the prevalence of SIM at different esophageal locations in patients who are at higher risk of developing esophageal adenocarcinoma (Caucasians) and patients with lower risk of developing esophageal adenocarcinoma (African-Americans). Eighty-seven unselected patients (42 Caucasians and 45 African-Americans) underwent routine upper endoscopy with biopsies from the proximal margin of columnar mucosa. We classified patients into those with a columnar-lined esophagus with SIM (CLE with SIM); CLE without SIM; or SIM with a normal-appearing gastroesophageal junction (SIM-GEJ). The prevalence of CLE with SIM, CLE without SIM, and SIM-GEJ was 28%, 10%, and 10% in Caucasians compared to 0%, 18% and 11% in African-Americans (P = 0.0001, 0.26, and 0.81, respectively). We found CLE with SIM only in patients with reflux symptoms at least twice a week. It is concluded that CLE with SIM is seen most commonly in patients thought to be at risk for esophageal adenocarcinoma (Caucasians with reflux symptoms). It is rarely seen in other groups with lower risk for this malignancy (African-Americans, nonrefluxers). Conversely, SIM-GEJ and CLE without SIM are common in all groups and are of questionable significance.
在过去二十年中,食管腺癌和胃贲门癌的发病率增长速度超过了其他任何癌症。巴雷特食管是这些恶性肿瘤唯一已知的危险因素。最近,人们开始重视食管活检中特殊肠化生(SIM)的意义。我们的目的是比较食管腺癌发病风险较高的患者(白种人)和食管腺癌发病风险较低的患者(非裔美国人)不同食管部位SIM的患病率。87例未经挑选的患者(42例白种人和45例非裔美国人)接受了常规上消化道内镜检查,并从柱状黏膜近端边缘取活检。我们将患者分为伴有SIM的柱状上皮食管(CLE伴SIM);不伴有SIM的CLE;或伴有外观正常的胃食管交界处的SIM(SIM-GEJ)。白种人中CLE伴SIM、不伴有SIM的CLE和SIM-GEJ的患病率分别为28%、10%和10%,而非裔美国人中分别为0%、18%和11%(P值分别为0.0001、0.26和0.81)。我们仅在每周至少出现两次反流症状的患者中发现了CLE伴SIM。结论是,CLE伴SIM最常见于被认为有食管腺癌风险的患者(有反流症状的白种人)。在其他患该恶性肿瘤风险较低的人群(非裔美国人、无反流者)中很少见。相反,SIM-GEJ和不伴有SIM的CLE在所有组中都很常见,其意义存疑。